Harry Hebert is a Principal Investigator (Tenure Track) at the University of Dundee, specialising in chronic pain pharmacoepidemiology, with a particular focus on neuropathic pain. He holds a BSc(Hons) in Genetics from the University of Nottingham (2009), an MSc in Human Molecular Genetics from Imperial College London (2010), and a PhD in Genetic Epidemiology from the University of Manchester (2015). Following his doctoral studies, Harry worked as a postdoctoral researcher in the Chronic Pain Research Group under Professors Blair H Smith and Lesley Colvin at Dundee. Appointed to his current role in 2024, he is now a PI on the PAINSTORM Dundee study, funded by the Advanced Pain Discovery Platform (APDP), and conducts research into the impact of gabapentinoid reclassification in the UK and risk factors for mortality among individuals with chronic pain and substance use disorders. His career goal is to improve the lives of people living with chronic pain by leading research that influences clinical guidelines, policy, and practice.